Time interval
By application date
- World epidemic prevention patent information table: 1912.04-2019.08
By announcement date
- World epidemic prevention patent information table: 1913.06-2019.10
Field display
| World epidemic prevention patent information table |
|---|
| Classification |
| Classification number |
| Agent |
| PDF download address |
| Abstract |
| Application date |
| Country/Organization |
| Public/announcement date |
| Citing patents |
| Main classification number |
| Application number |
| Inventor |
| Master Claims |
| Public/Announcement Number |
| Applicant |
Sample data
| Category | Classification number | Agent | Abstract | Application date | Country/Organization | Public/announcement date | Citing patents | Main classification number | Application number | Inventor | Master Claims | Public/Announcement Number | Applicant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/53;A61K31/664;A61K31/675;A61K31/683;A61K31/685;A61P31/12 | Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula (I): wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20160916 | WO(世界知识产权局) | 20170323 | WO2010002877A2;WO2014078778A2;WO2014116755A1;US2012071434A1;US8008264B2;US2012027752A1;WO2009132135A1;US2012009147A1;WO2012142085A1;WO2012075140A1;US2013143835A1 | A61K31/53 | WO2016US52092 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | WO2017049060A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K45/06 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20160916 | US(美国) | 20170316 | A61K31/706 | US201615267433 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | US2017071964A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K31/7056 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20190201 | US(美国) | 20190822 | A61K31/706 | US201916265016 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | US2019255085A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/12 | Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof. | 20180313 | WO(世界知识产权局) | 20180920 | A61K31/706 | WO2018US22166 | PERRON MICHEL JOSEPH | WO2018169946A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/724;A61K9/19;A61K47/40;A61K47/69;A61P31/12 | The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents. | 20180710 | US(美国) | 20190321 | A61K31/724 | US201816031620 | LARSON NATE | US2019083525A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;C07D519/00;C07F9/24;C07F9/6561 | Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20151029 | US(美国) | 20160505 | US8980865B2;US9243022B2;US9249174B2;US9605018B2;US9724360B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9701682B2;US2015133395A1 | C07D487/04 | US201514926063 | AXT STEVEN DONALD;BADALOV PAVEL ROBERTOVICH;BRAK KATRIEN;CAMPAGNA SILVIO;CHTCHEMELININE ANDREI;DOERFFLER EDWARD;FRICK MORIN MAE;GAO DETIAN;HEUMANN LARS V;HOANG BRITTANIE;LEW WILLARD;MILBURN ROBERT RONALD;NEVILLE SEAN TIMOTHY;ROSS BRUCE;RUEDEN ERIK;SCOTT ROBERT WILLIAM;SIEGEL DUSTIN;STEVENS ANDREW C;TADEUS CLARISSA;VIEIRA TIAGO;WALTMAN ANDREW W;WANG XIANGHONG;WHITCOMB MARK CHARLES;WOLFE LYDIA;YU CHIA-YUN | US2016122356A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K31/00;A61K31/53;A61K31/6615;A61K31/665;A61K31/675;A61K31/683;A61K31/685;A61K31/7056;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H11/00;C07H15/18 | Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20180222 | US(美国) | 20190409 | US8008264B2;US8318682B2;US8853171B2;US9724360B2;US9949994B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8415308B2;US8455451B2;US8871737B2;US8980865B2;US9090642B2;US9243022B2;US9249174B2;US9278990B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9605018B2;US9701682B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012071434A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013315868A1;US2013344028A2;US2015111839A1;US2015133395A1;US2015152116A1;AU2010295392B2;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2480559A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008055870A1;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2011011303A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2014078778A2;WO2014116755A1;WO2015069939A1;WO2016069825A1;WO2016069826A1;WO2016069827A1;WO2017049060A1 | A61K31/706 | US201815902690 | CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTIN | US10251898B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H15/18;A61K31/00;A61K31/53;A61K31/675;A61K31/685;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H7/06;C07H11/00 | Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20160824 | US(美国) | 20180424 | US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US9090642B2;US9724360B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013344028A2;US2015111839A1;US2015152116A1;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2015069939A1 | C07H15/18 | US201615246240 | CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTIN | US9949994B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20150204 | US(美国) | 20180904 | US9090642B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013281686A1;US2013344028A2;CA2367921C;CN1443189A;CN1498221A;CN1852915A;CN1291994C;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPS4117629B1;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010111381A2;WO2010135569A1;WO2011035231A1;WO2011035250A1;WO2011123672A1;WO2011123645A2;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1 | C07D487/04 | US201514613719 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US10065958B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | WO(世界知识产权局) | 20130919 | WO0232920A2;WO2009132123A1;WO2009132135A1;WO2012037038A1 | C07H19/23 | WO2013US30196 | CLARKE MICHAEL O' NEIL HANRAHAN | WO2013138236A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23 | as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20160930 | US(美国) | 20170427 | C07H19/23 | US201615282492 | CLARKE MICHAEL O' NEIL HANRAHAN | US2017114086A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61K45/06;C07H19/12 | as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20180622 | US(美国) | 20190117 | C07H19/23 | US201816016369 | CLARKE MICHAEL O' NEIL HANRAHAN | US2019016749A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/16;C07H7/06;C07H21/04 | Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I wherein R2 is halogen. The compounds, compositions, and methods provided particularly useful for the treatment of Human Influenza virus infections. | 20110912 | WO(世界知识产权局) | 20120322 | WO2010002877A2;WO03062257A1;WO0232920A2;WO0056734A1;WO2008089105A2;WO2008141079A1;WO2009132123A1;WO2009132135A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234A | A61K31/706 | WO2011US51249 | CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | WO2012037038A1 | GILEAD SCIENCES INC;CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07F9/6558;C07D487/04 | wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20170124 | US(美国) | 20170810 | C07F9/6558 | US201715414351 | CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | US2017226140A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Disclosed herein are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds, wherein the variables are as defined in the specification. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | NZ(新西兰) | 20161028 | C07H19/23 | NZ20130629996 | CLARKE MICHAEL O’ NEIL HANRAHAN | NZ629996A | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20171219 | AU(澳大利亚) | 20180118 | C07H19/23 | AU20170279590 | CLARKE MICHAEL O'NEIL HANRAHAN | AU2017279590A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/12;A61K31/706;A61K45/06 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | US(美国) | 20130919 | US2011230654A1;US8008264B2;US8318682B2;US8012941B2 | C07H19/12 | US201313793557 | CLARKE MICHAEL O'NEIL HANRAHAN | US2013243725A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H17/02;A61K31/706;A61K45/06 | Provided are methods for treating Orthomyxoviridue virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20140124 | US(美国) | 20140717 | C07H17/02 | US201414163251 | CLARKE MICHAEL O'NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | US2014200188A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H7/06;A61K9/00;A61K31/706;A61K45/06 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20141222 | US(美国) | 20150423 | US2008161324A1;US2010249068A1;US8853171B2;US8012941B2;US8318682B2;US8008264B2;WO2009132135A1 | C07H7/06 | US201414579348 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY A | US2015111839A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20170223 | AU(澳大利亚) | 20190502 | WO2009132135A1 | C07D309/10 | AU20170201230 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | AU2017201230B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the I 'position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20190723 | AU(澳大利亚) | 20190808 | C07D309/10 | AU20190208167 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | AU2019208167A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20110722 | WO(世界知识产权局) | 20120126 | WO2009132135A1;WO2010002877A2;WO2008141079A1;WO2008089105A2;WO0056734A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234A | C07D309/10 | WO2011US45102 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | WO2012012776A1 | GILEAD SCIENCES INC;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K39/395;A61P31/12;C07H19/04 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20110722 | US(美国) | 20120202 | US2008161324A1;WO2009132135A1 | A61K31/706 | US201113189373 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2012027752A1 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES;GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;C07F9/6561 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20150204 | US(美国) | 20150604 | C07D487/04 | US201514613719 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2015152116A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20180723 | US(美国) | 20190221 | C07D487/04 | US201816042085 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2019055251A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/18;C07H19/16;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20130603 | US(美国) | 20140227 | US6080791A;US6348587B1;WO0191737A2 | C07D473/18 | US201313908098 | STUYVER LIEVEN;WATANABE KYOICHI | US2014057863A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/00;A61P31/14 | The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae. | 20180427 | US(美国) | 20181206 | C07H19/00 | US201815964597 | BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATE | US2018346504A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61P31/14;A61K31/53;C07F9/6561 | The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy)phosphoryl)amino)propanoate (Formula I) for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Fil oviridae, Fiaviviridae,and Paramyxoviridae. | 20180427 | WO(世界知识产权局) | 20181108 | US201662325419P;US201514926062A;US2015057933W | A61P31/14 | WO2018US29974 | BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATE | WO2018204198A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20160128 | US(美国) | 20180118 | A61K31/08 | US201615546818 | RADTKE KATHERINE L;PETERS HANNAH L;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2018015052A1 | UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20180702 | US(美国) | 20181025 | A61K31/08 | US201816025284 | RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2018303768A1 | UNIV MARYLAND | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20190312 | US(美国) | 20190704 | A61K31/08 | US201916299379 | RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2019201352A1 | UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/12 | Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof. | 20180313 | WO(世界知识产权局) | 20180920 | A61K31/706 | WO2018US22166 | PERRON MICHEL JOSEPH | WO2018169946A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D307/12;A61K31/505;C07D239/10;C07D405/04 | Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections. | 20190307 | WO(世界知识产权局) | 20190912 | C07D307/12 | WO2019US21168 | PAINTER GEORGE R;PERRYMAN DAVID;BLUEMLING GREGORY R | WO2019173602A1 | UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/365;A61K31/381 | Infection by a Coronaviridae virus (e.g., a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compounds and derivatives thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compounds and derivatives thereof, either alone or in pharmaceutical compositions. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compounds and derivatives can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus. The nucleoside compounds are also for use in the manufacture of medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus (e.g., the SARS virus). In addition, the compounds are for use as medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus. | 20040427 | US(美国) | 20041223 | US2003050229A1;US2003060400A1;US6777395B2;US2002147160A1;US6812219B2 | A61K31/365 | US20040832945 | OLSEN DAVID B;TOMASSINI JOANNE E;MAO SHI-SHAN;CARROLL STEVEN S | US2004259934A1 | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/04;A61K31/7052;A61P31/12;C07H19/056;C07H19/06 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20110919 | WO(世界知识产权局) | 20120329 | WO2008086042A2;EP0457326A1;WO2009067409A1;WO2007020193A2 | C07H19/04 | WO2011US52217 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | WO2012040124A1 | ALIOS BIOPHARMA INC;BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708 | Disclosed herein are nucleosides, nucleotides and analogs thereof of formula I, II and III, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. In particular, viral infections caused by a virus selected from henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus. | 20130319 | NZ(新西兰) | 20161028 | A61K31/7068 | NZ20130629428 | SMITH DAVID BERNARD;DEVAL JEROME;BEIGELMAN LEONID;PRHAVC MARIJA;WANG GUANGYI | NZ629428A | ALIOS BIOPHARMA INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/70;A01N43/04;A61K31/7056;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K31/7105;A61K45/06;C07H19/00;C07H19/04;C07H19/048;C07H19/056;C07H19/067;C07H19/073;C07H19/09;C07H19/10;C07H19/11;C07H19/167;C07H19/173;C07H19/19;C07H19/20 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20110919 | US(美国) | 20141104 | US7094768B2;US7151089B2;US7629328B2;US5449664A;US5681940A;US5712378A;US6787525B1;US7915232B2;US2003064945A1;US2003124513A1;US2004259934A1;US2006040890A1;US2007042988A1;US2007066815A1;US2008008682A1;US2008039428A1;US2008107628A1;US2008161254A1;US2008188458A1;US2009176732A1;US2009318380A1;US2010151001A1;US2010234584A1;US2010240604A1;US2010249068A1;US2010297079A1;US2010331397A1;US2011020272A1;US2012070411A1;US2012071434A1;US2012165286A1;US2013164261A1;US2013165400A1;US2013252920A1;US2013253181A1;US2013281687A1;EP0371366A1;EP0457326A1;EP2177527A1;EP2166016A1;WO9221343A1;WO9614329A1;WO9816184A2;WO9816186A2;WO9914226A2;WO0034298A1;WO0066604A2;WO02100415A2;WO03026589A2;WO03026675A1;WO03039523A2;WO03070193A2;WO03070912A2;WO03073989A2;WO03102131A2;WO2004002422A2;WO2004002999A2;WO2004003000A2;WO2004014312A2;WO2004046159A1;WO2004052906A1;WO2004062676A1;WO2004080466A1;WO2004106356A1;WO2005000864A1;WO2005020884A2;WO2005021568A2;WO2006000922A2;WO2006094347A1;WO2007005779A2;WO2007020193A2;WO2007038859A1;WO2007038860A2;WO2007113538A1;WO2008005542A2;WO2008043704A1;WO2008043791A2;WO2008071571A1;WO2008083465A1;WO2008086042A2;WO2008089105A2;WO2008095040A2;WO2008100447A2;WO2008117047A1;WO2008121634A2;WO2008124384A2;WO2008125583A1;WO2008125599A1;WO2008136815A2;WO2009009951A1;WO2009025759A1;WO2009040269A1;WO2009064848A1;WO2009067409A1;WO2009069095A2;WO2009080836A2;WO2009085267A1;WO2009086192A1;WO2009086201A1;WO2009102318A1;WO2009120991A2;WO2009132123A1 | A61K31/70 | US201113236486 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US8877731B2 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR;ALIOS BIOPHARMA INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/20;C07H19/056;C07H19/06;C07H19/10;C07H19/16 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20141103 | US(美国) | 20150702 | US8877731B2;US8236779B2 | C07H19/20 | US201414531552 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US2015183819A1 | ALIOS BIOPHARMA INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/06;C07H19/056;C07H19/10;C07H19/16;C07H19/20 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20160523 | US(美国) | 20160915 | C07H19/06 | US201615161821 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US2016264610A1 | ALIOS BIOPHARMA INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | It is intended to provide a process for producing a functional molecule which shows high affinities for various targets. Namely, a process for producing a functional molecule which involves the step of producing a modified oligonucleotide sequence wherein a modified nucleotide n-mer (n representing an integer) containing a modified nucleoside having a substituent transferred into a nucleoside constituting a nucleic acid is polymerized at random to give the modified oligonucleotide sequence. A preferable embodiment thereof comprises the selection step of selecting a modified nucleotide sequence having an affinity for a target from among the modified nucleotide sequences the sequence-reading out step of amplifying the modified nucleotide sequence thus selected and determining its base sequence and the translation step of translating the sequence of the modified oligonucleotide sequence having the thus determined base sequence based on the relation between at least one of 4 nucleotide n-mers and the modified nucleotide n-mer referring to a relation table showing one-to-one combinations of the 4 nucleotides. | 20030314 | WO(世界知识产权局) | 20030925 | WO9203461A1;WO9640717A1;WO9921873A2;EP1201751A1 | A61K31/7115 | WO2003JP03087 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | WO03078623A1 | FUJITSU LTD;FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | A process for producing a functional molecule includes a forming step which forms a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid and a producing step which produces a modified oligonucleotide sequence by randomly polymerizing the modified nucleotide n-mer. A preferable embodiment thereof includes a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence on the basis of a relation table prepared by relating at least one of 4n kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer. | 20040917 | US(美国) | 20050616 | US5756291A;US6423493B1;US2002106679A1 | A61K31/7115 | US20040943150 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | US2005130195A1 | FUJITSU LTD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | The object of the present invention is to provide a process for producing a functional molecule having a high affinity to various targets. Accordingly, the process for producing the functional molecule includes a producing step which produces a modified oligonucleotide sequence by polymerizing randomly a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid. An aspect preferably comprises a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence, of which base sequence has been determined, on the basis of a relation table prepared by relating at least one of 4 kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer. | 20030314 | EP(欧洲专利局) | 20041222 | WO9205285A1;WO0024404A1;US5756291A;WO9214842A1;WO0023456A1 | A61K31/7115 | EP20030708622 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | EP1489171A1 | FUJITSU LTD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D311/36;C07D311/34 | PURPOSE: A dihydroxychromone derivative is provided to suppress SARS(severe acute respiratory syndrome)-coronavirus helicase activity which causes SARS. CONSTITUTION: A pharmaceutical composition for preventing and treating diseases caused by a coronavirus contains a compound of chemical formula 1 or a pharmaceutically acceptable salt, hydrate or isomer thereof as an active ingredient. The pharmaceutical composition further contains one or more pharmaceutically acceptable carriers, diluents, or excipients. The disease is SARS(severe acute respiratory syndrome). The pharmaceutical composition further contains an antiviral agent. The antiviral agent is a virus serine protease inhibitor, virus polymerase inihibitor, interferone alpha, or ribavirin. | 20090713 | KR(韩国) | 20110120 | C07D311/36 | KR20090063550 | CHONG YOU HOON;JEONG YONG JOO;LEE CHAE WOON | KR20110006083A | UNIV KONKUK IND COOP CORP | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/404;A61P31/14 | FIELD: medicine, virology, pharmacy. ^ SUBSTANCE: invention proposes an agent for treatment and prophylaxis of infection caused by coronaviruses, in particular, for treatment of atypical pneumonia (SARS), and pharmaceutical composition of indicated designation based on thereof. Agent represents 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole or 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole monohydrate hydrochloride (arbidol) known early as an immunomodulator and preparation used against influenza viruses. Invention provides reducing accumulation of coronaviruses (on example with TOPS virus) in lung. ^ EFFECT: valuable medicinal properties of agent. ^ 2 cl, 7 tbl, 9 ex | 20040421 | RU(俄罗斯联邦) | 20050720 | A61K31/404 | RU20040111871 | GLUSHKOV R G;MAKSIMOV V A;MART JANOV V A;KHAMITOV R A;SHUSTER A M | RU2256451C1 | ||||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/713;A61K38/21;A61P11/00;A61P31/12;A61K31/24;A61K31/4196;A61K31/7088;A61K48/00 | Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological "cascades" ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate. | 20051108 | AU(澳大利亚) | 20051215 | A61K31/713 | AU20050229761 | CARTER WILLIAM A;STRAYER DAVID | AU2005229761A1 | HEMISPHERX BIOPHARMA | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/073;A61K31/7064;A61P33/06;C07H19/067 | The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii). | 20061003 | AP(AP) | 20140331 | US4873228A | C07H19/073 | AP20080004436 | BELLO ANGELICA;FUJIHASHI MASAHIRO;KOTRA LAKSHMI P | AP2870A | UNIV HEALTH NETWORK | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/10;A61K31/7068;A61K31/7072;A61K45/06;C07B59/00;C07H19/06 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts. | 20151030 | US(美国) | 20171123 | C07H19/10 | US201515522056 | COATS STEVEN J;AMBLARD FRANCK;GARNIER-AMBLARD ETHEL;SCHINAZI RAYMOND F | US2017334941A1 | COCRYSTAL PHARMA INC;UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K47/48;C07F9/6512;A61K31/662;A61P3/14;A61P9/08;A61P19/00;A61P19/10;A61P31/00;A61P31/12;A61P35/00;A61P43/00;C07F9/38;C07F9/40;C07F9/6561;C07F9/6574;C07H19/10 | The present invention relates to phosphonate ester compounds formed by the covalent linking of a phosphonate selected from (a) cidofovir or tenofovir (b) an antiviral nucleoside phosphonate or an antiproliferative nucleoside phosphonate and (c) a derivative of cytosine arabinoside, gemcitabine, 5-fluorodeoxyuridine riboside, 2-chlorodeoxyadenosine, fludarabine or 1-beta-D-arabinofuranoxyl-guanine to an alkylpropanediol. The compounds are used in the preparation of medicaments for treating a viral disease in a subject in need thereof, wherein said viral disease is selected from the human immunodeficiency virus, influenza, the herpes simplex virus, the human herpes virus, the cytomegalovirus, the hepatitis B and C virus, the Epstein-Barr virus, the varicella zoster virus, the orthopox vi |